Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy

AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA and NAOHIRO FUJIMOTO
Anticancer Research August 2024, 44 (8) 3419-3426; DOI: https://doi.org/10.21873/anticanres.17162
AKINORI MINATO
1Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: a-minato{at}med.uoeh-u.ac.jp
NOBUKI FURUBAYASHI
2Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHISA TOMODA
3Department of Urology, Oita Prefectural Hospital, Oita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI MASAOKA
4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOOHYUN SONG
4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIFUMI HORI
5Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIJIRO KIYOSHIMA
6Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHITO NEGISHI
2Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENTARO KUROIWA
5Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NARIHITO SEKI
4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IKKO TOMISAKI
1Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOTONOBU NAKAMURA
2Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHI HARADA
1Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOHIRO FUJIMOTO
7Department of Urology, Kurate Hospital, Kurate, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 44 no. 8 3419-3426
DOI 
https://doi.org/10.21873/anticanres.17162
PMID 
39060065

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received June 6, 2024
  • Revision received June 19, 2024
  • Accepted June 20, 2024
  • Published online July 26, 2024.

Copyright & License 
Copyright © 2024 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. AKINORI MINATO1⇑,
  2. NOBUKI FURUBAYASHI2,
  3. TOSHIHISA TOMODA3,
  4. HIROYUKI MASAOKA4,
  5. YOOHYUN SONG4,
  6. YOSHIFUMI HORI5,
  7. KEIJIRO KIYOSHIMA6,
  8. TAKAHITO NEGISHI2,
  9. KENTARO KUROIWA5,
  10. NARIHITO SEKI4,
  11. IKKO TOMISAKI1,
  12. MOTONOBU NAKAMURA2,
  13. KENICHI HARADA1 and
  14. NAOHIRO FUJIMOTO7
  1. 1Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
  2. 2Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
  3. 3Department of Urology, Oita Prefectural Hospital, Oita, Japan;
  4. 4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan;
  5. 5Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan;
  6. 6Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan;
  7. 7Department of Urology, Kurate Hospital, Kurate, Japan
  1. Correspondence to: Akinori Minato (ORCID: 0000-0001-6303-1128), MD, Ph.D., Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. Tel: +81 936917446, Fax: +81 936038724, e-mail: a-minato{at}med.uoeh-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 44 (8)
Anticancer Research
Vol. 44, Issue 8
August 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA, NAOHIRO FUJIMOTO
Anticancer Research Aug 2024, 44 (8) 3419-3426; DOI: 10.21873/anticanres.17162

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA, NAOHIRO FUJIMOTO
Anticancer Research Aug 2024, 44 (8) 3419-3426; DOI: 10.21873/anticanres.17162
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma
  • Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial
  • Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
  • Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
  • Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
  • Google Scholar

More in this TOC Section

  • Laparotomy After Total Pelvic Exenteration: Current Status and Techniques for Ileal Conduit Preservation
  • Pregabalin for Opioid-resistant Neuropathic Pain in Bone Metastases
  • Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study
Show more Clinical Studies

Keywords

  • Urothelial carcinoma
  • enfortumab vedotin
  • avelumab
  • pembrolizumab
  • overall survival
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire